Table 5.
Percentages of cell subsets one year after first cycle of treatment in patients with secondary autoimmunity who had associations with baseline subsets.
| AIAEs+, n = 13 median (IQR) | AIAEs-, n = 26 median (IQR) | p value | ||
|---|---|---|---|---|
| T cells | CD4 T cells | 22.0 (17.5-27.4) | 18.9 (15.0-21.3) | ns |
| CD4 EM | 2.55 (2.00-3.67) | 4.15 (2.08-6.08) | ns | |
| CD4 TD | 0.70 (0.39-1.19) | 0.90 (0.60-1.45) | ns | |
| CD8+ TNF-alpha | 2.30 (1.92-7.64) | 2.63 (1.15-3.17) | ns | |
| B cells | Total B cells | 13.4 (5.06-18.2) | 10.3 (6.00-14.7) | ns |
| Naïve | 9.25 (3.14-16.8) | 8.29 (4.37-12.6) | ns | |
| Plasmablasts/plasma cells | 0.17 (0.09-0.28) | 0.09 (0.05-0.10) | 0.0058 |
AIAEs, Autoimmune adverse events; EM, effector memory; IQR, 25%-75% interquartile range; ns, not significant; TD, terminally differentiated. Percentages were calculated over total peripheral blood mononuclear cells. p-values were obtained using Mann–Whitney U test.